Skip to main content

Grossman Adam S's Form 4 filing

Adma Biologics, Inc. (ADMA) · filed Feb 17, 2026

Accession no.
0001140361-26-005888
Filed
Feb 17, 2026
Trade date
Feb 17, 2026
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $337.7K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Grossman Adam SCIK 0001542517Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 17, 2026Common StockMOption exerciseAcquired+15,000$5.40+$81,0002,305,379Direct
Feb 17, 2026Common StockSSaleDisposed−15,000$16.08F2−$241,2002,290,379Direct
Feb 17, 2026Common StockSSaleDisposed−6,000$16.08F2−$96,4802,284,379Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 17, 2026Common StockMOption exerciseDisposed−15,000$0.00$0705,950Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is the price at which the shares were sold.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)